Martin Janet L, Weenink Sarah M, Baxter Robert C
Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, New South Wales 2065, Australia.
J Biol Chem. 2003 Jan 31;278(5):2969-76. doi: 10.1074/jbc.M210739200. Epub 2002 Nov 13.
Insulin-like growth factor-binding protein-3 (IGFBP-3) is inhibitory to the growth of many breast cancer cells in vitro; however, a high level of expression of IGFBP-3 in breast tumors correlates with poor prognosis, suggesting that IGFBP-3 may be associated with growth stimulation in some breast cancers. We have shown previously in MCF-10A breast epithelial cells that chronic activation of Ras-p44/42 mitogen-activated protein (MAP) kinase confers resistance to the growth-inhibitory effects of IGFBP-3 (Martin, J. L., and Baxter, R. C. (1999) J. Biol. Chem. 274, 16407-16411). Here we show that, in the same cell line, IGFBP-3 potentiates DNA synthesis and cell proliferation stimulated by epidermal growth factor (EGF), a potent activator of Ras. A mutant of IGFBP-3, which fails to translocate to the nucleus and has reduced ability to cell-associate, similarly enhanced EGF action in these cells. By contrast, the structurally related IGFBP-5, which shares many functional features with IGFBP-3, was slightly inhibitory to DNA synthesis in the presence of EGF. IGFBP-3 primes MCF-10A cells to respond to EGF because pre-incubation caused a similar degree of EGF potentiation as co-incubation. In IGFBP-3-primed cells, EGF-stimulated EGF receptor phosphorylation at Tyr-1068 was increased relative to unprimed cells, as was phosphorylation and activity of p44/42 and p38 MAP kinases, but not Akt/PKB. Partial blockade of the p44/42 and p38 MAP kinase pathways abolished the potentiation by IGFBP-3 of EGF-stimulated DNA synthesis. Collectively, these findings indicate that IGFBP-3 enhances EGF signaling and proliferative effects in breast epithelial cells via increased EGF receptor phosphorylation and activation of p44/42 and p38 MAP kinase signaling pathways.
胰岛素样生长因子结合蛋白3(IGFBP-3)在体外对许多乳腺癌细胞的生长具有抑制作用;然而,乳腺癌组织中高水平的IGFBP-3表达与预后不良相关,这表明IGFBP-3在某些乳腺癌中可能与生长刺激有关。我们之前在MCF-10A乳腺上皮细胞中发现,Ras-p44/42丝裂原活化蛋白(MAP)激酶的持续激活赋予细胞对IGFBP-3生长抑制作用的抗性(Martin, J. L., and Baxter, R. C. (1999) J. Biol. Chem. 274, 16407-16411)。在此我们发现,在同一细胞系中,IGFBP-3可增强由表皮生长因子(EGF,一种Ras的强效激活剂)刺激的DNA合成和细胞增殖。一种无法转运至细胞核且与细胞结合能力降低的IGFBP-3突变体,同样增强了这些细胞中EGF的作用。相比之下,与IGFBP-3具有许多功能特征的结构相关蛋白IGFBP-5,在有EGF存在的情况下对DNA合成有轻微抑制作用。IGFBP-3使MCF-10A细胞对EGF产生反应,因为预孵育所引起的EGF增强程度与共孵育相似。在经IGFBP-3预处理的细胞中,相对于未预处理的细胞,EGF刺激的EGF受体Tyr-1068位点磷酸化增加,p44/42和p38 MAP激酶的磷酸化及活性也增加,但Akt/PKB未增加。部分阻断p44/42和p38 MAP激酶途径可消除IGFBP-3对EGF刺激的DNA合成的增强作用。总的来说,这些发现表明IGFBP-3通过增加EGF受体磷酸化以及激活p44/42和p38 MAP激酶信号通路,增强了乳腺上皮细胞中的EGF信号传导和增殖效应。